New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
06:37 EDTBLUEbluebird bio price target raised to $58 from $51 at Piper Jaffray
Piper Jaffray raised its price target for bluebird bio (BLUE) shares to $58 saying the beta thal market provides opportunity for both bluebird and Biogen (BIIB). Piper sees a possible market split should both companies' data remain positive. It keeps an Overweight rating on bluebird bio.
News For BLUE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 22, 2015
07:43 EDTBLUEbluebird bio reinstated with a Buy at BofA/Merrill
Subscribe for More Information
January 21, 2015
12:27 EDTBLUEbluebird bio price target raised to $146 from $94 at Wedbush
Subscribe for More Information
January 20, 2015
13:21 EDTBLUECAR T-Cell therapy drug stocks down sharply following NY Times story
Shares of biotechnology companies that are developing chimeric antigen receptor T cells or CAR T therapy drugs are falling sharply after a New York Times story titled "Riding High, Biotech Firms Remain Wary." WHAT'S NEW: Over the weekend, the New York Times published the story that struck a cautionary tone on the CAR-T therapy drugs. In this form of cancer treatment the patients own immune system cells are genetically manipulated to battle tumors. The New York Times story noted that there were some notable outcomes in the treatment of leukemia and lymphoma with the CAR T treatments but highlighted that the "technique is still early in development and can cause severe side effects." WHAT'S NOTABLE. Early last week, Intrexon (XON) and its oncology partner, ZIOPHARM Oncology (ZIOP), announced an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sub-licensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies. Both companies' shares were up sharply following the announcement ZIOPHARM was up around 55% and Intrexon up over 30% the day following the announcement. PRICE ACTION: Shares of drug companies in the space are sharply lower in midday trading, with ZIOPHARM Oncology and Kite Pharma (KITE) each down over 9%, Intrexon down almost 12%, and Bellicum Pharmaceutical (BLCM) and bluebird bio (BLUE) each down almost 5%. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use